Not applicableEnded earlyNCT03473496What this trial is testingCAR-T Cells Therapy in Relapsed/Refractory Multiple MyelomaWho this might be right forRelapsed/Refractory Multiple Myeloma(MM) Zhujiang Hospital 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07771361What this trial is testingBAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple MyelomaWho this might be right forNon-Hodgkin Lymphoma Refractory/ RelapsedMultiple Myeloma RefractoryMultiple Myeloma in Relapse+5 more Luminary Therapeutics 90
Testing effectiveness (Phase 2)Looking for participantsNCT06518551What this trial is testingElotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMWho this might be right forMyelomaMultiple MyelomaRefractory Multiple Myeloma Omar Nadeem, MD 49
Very early researchLooking for participantsNCT07429721What this trial is testingA Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.Who this might be right forMultiple Myeloma (MM) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 24
Very early researchNot Yet RecruitingNCT07628595What this trial is testingSafety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma (MM) The First Affiliated Hospital with Nanjing Medical University 19
Testing effectiveness (Phase 2)Study completedNCT01946477What this trial is testingPomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingWho this might be right forMultiple Myeloma Celgene 186
Early research (Phase 1)Ended earlyNCT01985477What this trial is testingRevlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple MyelomaWho this might be right forMyeloma M.D. Anderson Cancer Center 2
Testing effectiveness (Phase 2)Ended earlyNCT00293111What this trial is testingSafety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)Who this might be right forMultiple Myeloma Cephalon 30
Not applicableStudy completedNCT04721002What this trial is testingStudy to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)Who this might be right forMultiple Myeloma (MM) AbbVie 514
Not applicableApproved For MarketingNCT05164250What this trial is testingCompassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)Who this might be right forMultiple Myeloma Regeneron Pharmaceuticals
Not applicableStudy completedNCT05742217What this trial is testingLearn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related DiseasesWho this might be right forRelapse Multiple MyelomaRefractory Multiple Myeloma Pfizer 121
Not applicableLooking for participantsNCT07248176What this trial is testingUniversal CAR-T Cell Therapy for MMWho this might be right forMultiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory Bioray Laboratories 6
Very early researchLooking for participantsNCT07771803What this trial is testingA Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)Who this might be right forAML (Acute Myeloid Leukemia)Multiple Myeloma Refractory Roger Strair 20
Very early researchLooking for participantsNCT07101705What this trial is testingAn Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological MalignanciesWho this might be right forMultiple Myeloma (MM)Non-Hodgkin Lymphoma (NHL) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 40
Early research (Phase 1)Study completedNCT00258245What this trial is testingArsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Barbara Ann Karmanos Cancer Institute 5
Not applicableLooking for participantsNCT07100067What this trial is testingLCAR-F33S in Treatment of Relapsed/Refractory Multiple MyelomaWho this might be right forRelapsed/Refractory Multiple Myeloma(MM) Nanjing Legend Biotech Co. 35
Testing effectiveness (Phase 2)Ended earlyNCT00499239What this trial is testingA Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)Who this might be right forNon-Hodgkin's LymphomaChronic Lymphocytic LeukemiaMultiple Myeloma Gilead Sciences 32
Early research (Phase 1)UnknownNCT05052970What this trial is testingMitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMWho this might be right forRelapsed or Refractory Multiple Myeloma CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 60
Early research (Phase 1)Study completedNCT01575925What this trial is testingStudy of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)Who this might be right forMultiple MyelomaRenal Impairment Celgene 25
Testing effectiveness (Phase 2)Study completedNCT07102706What this trial is testingPhase I Trial of GR1803 Injection in Patients With RRMMWho this might be right forMultiple Myeloma (MM) Genrix (Shanghai) Biopharmaceutical Co., Ltd. 76